Free provider profile
SANDEEP GUPTA, MD
NPI 1972577005
Individual
Psychiatry & Neurology, Psychiatry
Active registration
Save to rep workspaceNPI registry Registry record
Source: CMS NPPES registry, updated continuously. This record was last updated 2013-04-01.
501 W 14TH STREET WILMINGTON HOSPITAL, DEPARTMENT OF PSYCHIATRY, WILMINGTON, DE, 19801
302-421-2100
Single practice location
Enumerated 2006-02-15
- — Registration is active in NPPES.
- — Individual clinician record — reachable, but usually not the buyer.
- — Practice phone number is published.
- — Full street address on file for route planning.
- — Record last updated 13 years ago.
Medicare Part D prescribing
Source: CMS Medicare Part D Prescribers by Provider, most recent public year.
Part D claims
4,730
Medicare patients
302
Part D drug cost
$809,188
Brand-name share
9.6%
of this prescriber's Part D claims
| Drug | Claims | Medicare cost |
|---|---|---|
| Vraylar (Cariprazine Hcl) | 88 | $181,433 |
| Spravato (Esketamine Hcl) | 116 | $140,547 |
| Ingrezza (Valbenazine Tosylate) | 12 | $102,675 |
| Rexulti (Brexpiprazole) | 31 | $77,684 |
| Caplyta (Lumateperone Tosylate) | 18 | $30,914 |
| Lybalvi (Olanzapine/Samidorphan Malate) | 15 | $24,040 |
| Vyvanse (Lisdexamfetamine Dimesylate) | 47 | $18,293 |
| Lurasidone Hcl (Lurasidone Hcl) | 24 | $14,314 |
Want their full drug mix and peer benchmark? Run the free Part D prescriber lookup.
Spravato (esketamine) Medicare billing
Source: CMS Medicare Part B fee-for-service, HCPCS G2082/G2083.
2024143 sessions · 11 patients · $133,822
Full Spravato label-compliance detail — sessions per patient against the FDA label, risk flags and year-over-year trend.
- Registry data comes straight from CMS NPPES, which lists registration, not activity — a listed practice may have moved or closed.
- Part D covers Medicare prescription drug enrollees only. Commercial, Medicaid and cash-pay prescribing is not included, so these figures are a floor on real volume, not the whole picture.
- CMS publishes the Part D file annually, roughly two years behind the prescribing year. Drugs with 10 or fewer claims are suppressed.